Silo Pharma Inc. (NASDAQ: SILO) announced that the European Patent Office has issued a Rule 71(3) communication indicating its intent to grant a patent for a PTSD prevention therapy. The patent application, titled "Prophylactic Efficacy of Serotonin 4 Receptor Agonists Against Stress," is exclusively licensed from Columbia University.

The allowed claims cover methods of preventing stress-induced fear and depressive-like behavior using serotonin 4 receptor agonists. The approach targets pathways associated with stress resilience rather than symptom management.

"This is a high-value milestone that strengthens our global intellectual property position and underscores the potential of our 5-HT4 program," said Eric Weisblum, CEO of Silo Pharma. "We believe this approach represents a compelling shift toward proactive treatment of stress-related disorders, which remain a massive and underserved market."

The patent, once granted, will protect major European markets. The company is evaluating Unitary Patent protection and national validations to maximize geographic coverage.

Silo Pharma is a developmental-stage biopharmaceutical company focused on developing novel formulations and drug delivery systems for traditional therapeutics and psychedelic treatments. The company's portfolio includes programs targeting stress-induced psychiatric disorders, chronic pain, and central nervous system diseases.